Oxomollugin, an oxidized substance in mollugin, inhibited LPS-induced NF-κB activation via the suppressive effects on essential activation factors of TLR4 signaling

Yuki Nakajima,Naohide Tsuboi,Kumiko Katori,Maigunuer Waili,Alfarius Eko Nugroho,Kazunori Takahashi,Hitomi Nishino,Yusuke Hirasawa,Yoko Kawasaki,Yukihiro Goda,Toshio Kaneda,Hiroshi Morita
DOI: https://doi.org/10.1007/s11418-024-01798-y
IF: 3.1921
2024-04-04
Journal of Natural Medicines
Abstract:Oxomollugin is a degraded product of mollugin and was found to be an active compound that inhibits LPS-induced NF-κB activation. In this study, we investigated the inhibitory activity of oxomollugin, focusing on TLR4 signaling pathway, resulting in NF-κB activation. Oxomollugin inhibited the LPS-induced association of essential factors for initial activation of TLR4 signaling, MyD88, IRAK4 and TRAF6. Furthermore, oxomollugin showed suppressive effects on LPS-induced modification of IRAK1, IRAK2 and TRAF6, LPS-induced association of TRAF6-TAK1/TAB2, and followed by IKKα/β phosphorylation, which critical in signal transduction leading to LPS-induced NF-κB activation. The consistent results suggested that oxomollugin inhibits LPS-induced NF-κB activation via the suppression against signal transduction in TLR4 signaling pathway.
pharmacology & pharmacy,chemistry, medicinal
What problem does this paper attempt to address?